EGFR and non-small cell lung carcinoma: Treue et al. (2019) reported EGFR-mutated NSCLC with whole exome sequencing data, phosphorylated protein data and computational models, and identified three potential biomarkers for therapy targets. APOBEC, a DNA deaminase, was identified as a gene of mutational heterogeneity which might be associated with tumour migration (Roper et al., 2019). Although a large amount of work have been done on NSCLC and SCLC, the essential differences between NSCLC and SCLC remain to be fully characterized (Sutherland et al., 2011).